3D Systems Shares Slip for Seven Consecutive Sessions
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 12 2026
0mins
Source: seekingalpha
- Stock Price Decline: 3D Systems Corporation (DDD) shares have slipped for seven consecutive trading sessions, indicating market concerns about its future performance, which could undermine investor confidence and lead to capital outflows.
- Aerospace and Defense Focus: While 3D Systems' positioning in the aerospace and defense sector has garnered some market interest, analysts caution that chasing the stock at this time may be unwise, potentially increasing investment risks.
- Earnings Preview Impact: With the Q1 2026 earnings report approaching, market expectations for the company's performance are low, which may exacerbate stock price volatility and influence short-term investment decisions.
- Market Sentiment Weakness: The ongoing stock price decline and cautious outlook regarding upcoming earnings may contribute to a lackluster market sentiment, thereby affecting the company's performance in capital markets and its ability to raise funds.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy DDD?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on DDD
Wall Street analysts forecast DDD stock price to rise
4 Analyst Rating
1 Buy
3 Hold
0 Sell
Hold
Current: 3.150
Low
5.00
Averages
5.00
High
5.00
Current: 3.150
Low
5.00
Averages
5.00
High
5.00
About DDD
3D Systems Corporation provides comprehensive three-dimensional (3D) printing and digital manufacturing solutions, including 3D printers for plastics and metals, materials, software, and services, including maintenance, advanced manufacturing and applications engineering. The Company’s segments include Healthcare Solutions and Industrial Solutions. The Healthcare Solutions segment serves industry verticals, including dental, medical devices, personalized health services and regenerative medicine. The Industrial Solutions segment serves industry verticals, including aerospace, defense, transportation and general manufacturing. The Company architects solutions specific to customers’ needs through a combination of materials, hardware platforms, software, professional services and advanced manufacturing. It markets its products and services through subsidiaries in North America and South America, Europe and the Middle East and Asia Pacific and Oceania.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
3D Systems Corporation Shows Signs of Profitability Improvement
- Profitability Signs: Craig-Hallum analyst Greg Palm raised the price target for 3D Systems Corporation from $2.50 to $3.00 while maintaining a Hold rating, citing early signs of profitability after years of losses.
- Significant Revenue Growth: In Q1 2026, 3D Systems reported revenue of $95.5 million, an 11% year-over-year increase, with the Healthcare Solutions segment leading at a 21% growth to $50.1 million, indicating strong market demand.
- Cost Control Success: The company implemented a substantial cost-cutting program in Q1, resulting in a 35% year-over-year reduction in non-GAAP operating expenses and locking in over $55 million in annualized savings, while non-GAAP gross margin improved to 36.1%, up 6 percentage points.
- Cautious Market Reaction: Despite the improved performance, analyst Palm noted that these results might be an outlier, as the stock did not react positively as expected, indicating market skepticism regarding the sustainability of the profitability trend.
See More
Conexeu Sciences Inc. Goes Public, Pioneering a New Era in Regenerative Medicine
- IPO Milestone: Conexeu Sciences Inc. successfully debuted on Nasdaq on May 21, 2026, with 25,269,996 shares outstanding and a fully diluted total of 35,238,222 shares, marking a significant advancement in regenerative medicine and enhancing its market competitiveness.
- Innovative Product Launch: The company unveiled its 3D bioprinted regenerative breast matrix, B.R.E.A.S.T.™, designed to provide a temporary scaffold for patients post-mastectomy, targeting over 100,000 women annually who opt out of reconstruction, thus opening a larger market opportunity.
- Platform Advantage: Conexeu's CXU™ platform can be applied across multiple tissue regeneration products, streamlining product development processes and targeting multi-billion-dollar markets in wound care, periodontal applications, and facial contouring, indicating vast market potential.
- Regulatory Strategy: The company plans to submit a 510(k) application in early 2027, transitioning its products from investigational to commercial status, further solidifying its leadership position in the regenerative medicine sector.
See More
Conexeu Sciences Inc. Goes Public, Pioneering a New Era in Regenerative Medicine
- IPO Milestone: Conexeu Sciences Inc. debuted on Nasdaq on May 21, 2026, with 25,269,996 shares outstanding and 35,238,222 on a fully diluted basis, marking a significant advancement in regenerative medicine and expected to enhance its market competitiveness.
- Innovative Product Launch: The company unveiled B.R.E.A.S.T.™, a 3D-printed regenerative breast matrix designed to provide a temporary scaffold for women post-mastectomy, addressing a market gap faced by over 100,000 women annually, indicating substantial market potential.
- Platform Technology Advantage: Conexeu's CXU™ platform can be applied across multiple tissue regeneration products, streamlining product development processes and is expected to drive expansion into multi-billion-dollar markets such as wound care, periodontal applications, and facial contouring, enhancing overall business growth potential.
- Regulatory Outlook: The company plans to submit a 510(k) application in early 2027, marking a transition from preclinical to commercialization; if approved, this will open new revenue streams and bolster investor confidence.
See More
3D Systems Exceeds Q1 Revenue Expectations
- Revenue Growth: 3D Systems reported Q1 2026 revenue of $95.54 million, reflecting a 1.1% year-on-year increase that surpassed analyst expectations of $92.2 million, indicating a recovery in market demand and competitive positioning.
- Improved Adjusted EPS: The company posted an adjusted loss of $0.01 per share, significantly better than the anticipated loss of $0.08, achieving an 87.9% improvement that highlights effective cost management and successful new product launches.
- Strong Demand in Healthcare and Aerospace: The company experienced double-digit growth in medical parts manufacturing and printer sales, driven by rising demand for titanium and cobalt chrome implants, showcasing its expansion in high-reliability markets and the success of its product portfolio.
- Cost Efficiency Enhancements: 3D Systems implemented over $55 million in annualized cost savings, which significantly improved margins, and expects to complete these efficiency initiatives by the end of the next quarter, further strengthening its financial stability.
See More
3D Systems Q1 2026 Earnings Call Insights
- Industry Recovery Signals: CEO Jeffrey Graves highlighted that the additive manufacturing sector is emerging from a multi-year trough, with Q1 printer and material sales showing double-digit growth, particularly in healthcare materials, indicating a rebound in market demand.
- Med Tech Growth: Demand for medical parts manufacturing was driven by titanium spinal implants and cobalt chrome joint implants, with revenue from the DMP 350 metal printer leading printer sales; although growth was partially offset by a temporary disruption in a key customer's operations, a solid rebound in demand is expected in Q2.
- Dental Market Expansion: 3D Systems gained U.S. regulatory approval for Vertex, doubling the market size, and the successful deployment of the NextDent denture platform at ROE Dental Laboratory signifies deeper penetration in the dental sector, which is anticipated to drive future sales growth.
- Cautious Financial Outlook: The company guided Q2 revenue between $93M and $95M, down from $95.5M in Q1, and while overall demand remains healthy, management is cautious about macroeconomic volatility, emphasizing the need to focus on product mix and seasonal factors.
See More
3D Systems Shares Slip for Seven Consecutive Sessions
- Stock Price Decline: 3D Systems Corporation (DDD) shares have slipped for seven consecutive trading sessions, indicating market concerns about its future performance, which could undermine investor confidence and lead to capital outflows.
- Aerospace and Defense Focus: While 3D Systems' positioning in the aerospace and defense sector has garnered some market interest, analysts caution that chasing the stock at this time may be unwise, potentially increasing investment risks.
- Earnings Preview Impact: With the Q1 2026 earnings report approaching, market expectations for the company's performance are low, which may exacerbate stock price volatility and influence short-term investment decisions.
- Market Sentiment Weakness: The ongoing stock price decline and cautious outlook regarding upcoming earnings may contribute to a lackluster market sentiment, thereby affecting the company's performance in capital markets and its ability to raise funds.
See More
3D Systems Corporation Shows Signs of Profitability Improvement
- Profitability Signs: Craig-Hallum analyst Greg Palm raised the price target for 3D Systems Corporation from $2.50 to $3.00 while maintaining a Hold rating, citing early signs of profitability after years of losses.
- Significant Revenue Growth: In Q1 2026, 3D Systems reported revenue of $95.5 million, an 11% year-over-year increase, with the Healthcare Solutions segment leading at a 21% growth to $50.1 million, indicating strong market demand.
- Cost Control Success: The company implemented a substantial cost-cutting program in Q1, resulting in a 35% year-over-year reduction in non-GAAP operating expenses and locking in over $55 million in annualized savings, while non-GAAP gross margin improved to 36.1%, up 6 percentage points.
- Cautious Market Reaction: Despite the improved performance, analyst Palm noted that these results might be an outlier, as the stock did not react positively as expected, indicating market skepticism regarding the sustainability of the profitability trend.
See More
Conexeu Sciences Inc. Goes Public, Pioneering a New Era in Regenerative Medicine
- IPO Milestone: Conexeu Sciences Inc. successfully debuted on Nasdaq on May 21, 2026, with 25,269,996 shares outstanding and a fully diluted total of 35,238,222 shares, marking a significant advancement in regenerative medicine and enhancing its market competitiveness.
- Innovative Product Launch: The company unveiled its 3D bioprinted regenerative breast matrix, B.R.E.A.S.T.™, designed to provide a temporary scaffold for patients post-mastectomy, targeting over 100,000 women annually who opt out of reconstruction, thus opening a larger market opportunity.
- Platform Advantage: Conexeu's CXU™ platform can be applied across multiple tissue regeneration products, streamlining product development processes and targeting multi-billion-dollar markets in wound care, periodontal applications, and facial contouring, indicating vast market potential.
- Regulatory Strategy: The company plans to submit a 510(k) application in early 2027, transitioning its products from investigational to commercial status, further solidifying its leadership position in the regenerative medicine sector.
See More
Conexeu Sciences Inc. Goes Public, Pioneering a New Era in Regenerative Medicine
- IPO Milestone: Conexeu Sciences Inc. debuted on Nasdaq on May 21, 2026, with 25,269,996 shares outstanding and 35,238,222 on a fully diluted basis, marking a significant advancement in regenerative medicine and expected to enhance its market competitiveness.
- Innovative Product Launch: The company unveiled B.R.E.A.S.T.™, a 3D-printed regenerative breast matrix designed to provide a temporary scaffold for women post-mastectomy, addressing a market gap faced by over 100,000 women annually, indicating substantial market potential.
- Platform Technology Advantage: Conexeu's CXU™ platform can be applied across multiple tissue regeneration products, streamlining product development processes and is expected to drive expansion into multi-billion-dollar markets such as wound care, periodontal applications, and facial contouring, enhancing overall business growth potential.
- Regulatory Outlook: The company plans to submit a 510(k) application in early 2027, marking a transition from preclinical to commercialization; if approved, this will open new revenue streams and bolster investor confidence.
See More
3D Systems Exceeds Q1 Revenue Expectations
- Revenue Growth: 3D Systems reported Q1 2026 revenue of $95.54 million, reflecting a 1.1% year-on-year increase that surpassed analyst expectations of $92.2 million, indicating a recovery in market demand and competitive positioning.
- Improved Adjusted EPS: The company posted an adjusted loss of $0.01 per share, significantly better than the anticipated loss of $0.08, achieving an 87.9% improvement that highlights effective cost management and successful new product launches.
- Strong Demand in Healthcare and Aerospace: The company experienced double-digit growth in medical parts manufacturing and printer sales, driven by rising demand for titanium and cobalt chrome implants, showcasing its expansion in high-reliability markets and the success of its product portfolio.
- Cost Efficiency Enhancements: 3D Systems implemented over $55 million in annualized cost savings, which significantly improved margins, and expects to complete these efficiency initiatives by the end of the next quarter, further strengthening its financial stability.
See More
3D Systems Q1 2026 Earnings Call Insights
- Industry Recovery Signals: CEO Jeffrey Graves highlighted that the additive manufacturing sector is emerging from a multi-year trough, with Q1 printer and material sales showing double-digit growth, particularly in healthcare materials, indicating a rebound in market demand.
- Med Tech Growth: Demand for medical parts manufacturing was driven by titanium spinal implants and cobalt chrome joint implants, with revenue from the DMP 350 metal printer leading printer sales; although growth was partially offset by a temporary disruption in a key customer's operations, a solid rebound in demand is expected in Q2.
- Dental Market Expansion: 3D Systems gained U.S. regulatory approval for Vertex, doubling the market size, and the successful deployment of the NextDent denture platform at ROE Dental Laboratory signifies deeper penetration in the dental sector, which is anticipated to drive future sales growth.
- Cautious Financial Outlook: The company guided Q2 revenue between $93M and $95M, down from $95.5M in Q1, and while overall demand remains healthy, management is cautious about macroeconomic volatility, emphasizing the need to focus on product mix and seasonal factors.
See More
3D Systems Shares Slip for Seven Consecutive Sessions
- Stock Price Decline: 3D Systems Corporation (DDD) shares have slipped for seven consecutive trading sessions, indicating market concerns about its future performance, which could undermine investor confidence and lead to capital outflows.
- Aerospace and Defense Focus: While 3D Systems' positioning in the aerospace and defense sector has garnered some market interest, analysts caution that chasing the stock at this time may be unwise, potentially increasing investment risks.
- Earnings Preview Impact: With the Q1 2026 earnings report approaching, market expectations for the company's performance are low, which may exacerbate stock price volatility and influence short-term investment decisions.
- Market Sentiment Weakness: The ongoing stock price decline and cautious outlook regarding upcoming earnings may contribute to a lackluster market sentiment, thereby affecting the company's performance in capital markets and its ability to raise funds.
See More
